Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Journal Volume
75
Journal Issue
5
Pages
743
Date Issued
2022-09-14
Author(s)
Huang, Hung Ling
Lee, Jung Yu
Lo, Yu Shu
Liu, I Hsin
Huang, Sing Han
Huang, Yu Wei
Lee, Chih Hsin
Cheng, Meng Hsuan
Lu, Po Liang
Yang, Jinn Moon
Chong, Inn Wen
Abstract
Systemic drug reaction (SDR) is a major safety concern with weekly rifapentine plus isoniazid for 12 doses (3HP) for latent tuberculosis infection (LTBI). Identifying SDR predictors and at-risk participants before treatment can improve cost-effectiveness of the LTBI program.
Subjects
interpretable machine learning; latent tuberculosis infection; rifapentine; systemic drug reaction; transcriptome
Publisher
OXFORD UNIV PRESS INC
Type
journal article